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Abstract 
Background: The outcome of antiretroviral treatment, survival patterns and associated determining factors in public 
hospitals are not well known. Thus a longitudinal study is vital to understand the pattern of survival and treatment 
outcome.  
Objective: To assess the outcome of antiretroviral treatment in rural public hospitals in South Nations, Nationalities 
and Peoples Region, Ethiopia. 
Method: A historical retrospective cohort study design was used for patients visiting hospitals from January 1, 2005 to 
January 31, 2009. A total of 5,664 patient records were examined from eight randomly selected public hospitals. 
Kaplan-Meier models were used to estimate mortality and Cox proportional hazards models to identify predictors of 
mortality. 
Results: The median age was 30 years and 73.6% were in the age group 25-40 while the higher HIV risk age group 
14-24 covered only 12.8%. The proportion of females was 56.3%. The cumulative proportions of survivals were 92%, 
90%, 88% and 86% at months 6, 12, 24 and 36 respectively. The hazard of death was higher in male (AHR: 1.632, CI: 
1.309-2.034) and those who had a baseline CD4 cell count < 50 cells /ml compared to these with a count of above 200 
(AHR: 3.176, CI: 2.304- 4.434). Patients with WHO stage IV at baseline had a higher risk of death compared to these 
with a WHO stage I (AHR: 5.603, CI: 1.753-17.905). 
Conclusions:  There is an indication of improvement of survival in the patient population. An advanced disease stage, 
Low CD4 cell count, gender and timing of ARV regimen combinations had significant contribution in determining a 
longer survival time. Priority should thus be given to identify HIV-infected individuals and start ART earlier in the 
course of their illness.  [Ethiop. J. Health Dev. 2011;25(2):102-109] 
 
Introduction 
The Acquired Immune Deficiency Syndrome (AIDS) 
disease has been one of the most destructive epidemics to 
hit Ethiopia. There were 977,394 people living with the 
virus, and of these 258,264 require antiretroviral 
treatment (ART). Adults and adolescents account for 
24% of antiretroviral (ARV) service coverage by 
December 2006 (1). A Federal Ministry of Health 
(FMoH) report showed that 95,756 patients started ART 
treatment in Ethiopia. Out of these 71,773 (74.95%) 
patients are presently on ART (2).  
 
The national antiretroviral initiation criteria for both 
adults and adolescents states that, in places where CD4 
cell count is available, WHO clinical stage IV, 
irrespective of CD4 cell count, WHO stage III and if 
CD4 cell count is less than 350 and all WHO stage IV 
and CD4 cell count is less than 50 are criteria for eligible 
patients to start ART. However, for places where CD4 
cell count is not available, WHO stage IV and WHO 
stage III, irrespective of TLC, WHO stage II and if TLC 
is less than or equal to 1200 are eligible to initiate ART 
treatment. Large numbers of people, without age and 
gender limitation, need to access free antiretroviral 
treatment and prolong survival (3). 
 
Prevention of HIV infection, retention of patients in 
chronic care and retention of physicians in the public 
health care facilities need urgent attention for effective 
and sustainable HIV/AIDS health system responses in the 
long term (4). The widespread availability of ART has 
led to a substantial decline in mortality (5). 
 
A study in South Africa concluded that scaling up ART 
provision was associated with reduced early mortality 
(6). Early mortality rates in sub-Saharan Africa are very 
high; between 8 to 26 % of patients die in the first year of 
ART with most deaths occurring in the first few months 
(7). 
 
Clinical staging and BMI (body mass index) could be 
important screening tools to identify and target 
individuals who are still at high risk of early death. A 
study in South Africa showed that risk factors associated 
with mortality were WHO stage IV disease, baseline 
CD4 count and malnutrition (8). Mortality was high in 
CD4 cell count less than 50 for both experienced and 
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non-experienced treating physician in comparison to 
CD4 cell count above 200 strata (9). 
 
A study in northern Uganda of ART patients’ showed 
that mortality is comparable in patients who were treated 
in conflict and peaceful areas and low income settings 
(10). An Indian experience showed that monitoring body 
weight during follow up emerged as an inexpensive 
predicators of treatment failure in a resource poor setting 
(11). 
 
A better knowledge of prognostic factors would allow 
closer follow up and more targeted interventions to 
improve survival. Little information is available on a 
longer follow up antiretroviral treatment outcome. 
Hence, the objective of this study was to assess the 
outcomes of antiretroviral treatment and predicting 
factors in rural public hospitals in the South Nations, 
Nationalities and Peoples Region, (SNNPR) Ethiopia. It 
also described the pattern of CD4 cell count and body 
weight change at months 0, 6, 12 and 24. 
 
Methods 
The study was made in eight hospitals located in South 
Nations, Nationalities and Peoples Region (SNNPR). The 
study population were all adults age above 14 years, who 
started ART treatment between January 1, 2005 and 
January 31, 2009. 
 
A retrospective historical cohort study with single stage 
cluster sample of unequal size was employed for the 
study.  Assuming a homogeneous ART treatment care 
throughout the region, eight hospitals were randomly 
selected among sixteen hospitals.  
 
The sample size was calculated to detect the difference 
between two proportions formula to allow comparisons 
using gender as a factor with the following assumptions; 
5% type I error, 80% power, ratio of male to female 1:1, 
19.8% and 14.4% proportion of crude death rate in males 
and female, adjustment of lost follow up rate of 21% of 
the one year follow up study in Zambia were assumed 
(12). Moreover, a 0.001 intra-class correlation was 
considered. Based on the above assumptions the 
minimum sample size required for the study was 2, 311. 
 
The study used secondary data collected routinely in the 
hospitals and entered in an ART register database. De-
identified databases were backed up and merged in ART 
data warehouse designed by the principal investigator. As 
a result, the study used a sample size of 5,664 patient 
records out of 20,451 total patient records in the region. 
Since the number of records was higher than the 
minimum required sample size increasing the importance 
of the study. 
 
The outcome variable was death and follow up time from 
the start of ART to one of the following event (LOST, 
DROP, TRANSFER OUT, STOP, DEAD) until the end 
of the study which was January 31, 2009). Whichever 
outcome occurred first was considered. The covariates 
included in the Cox hazard model were sex, age, WHO 
stage, functional status, CD4 cell count and presence and 
absence of Nevirapine drug in ARV regimen at baseline. 
 
Operational Definitions:  
The following operational definitions were obtained from 
routine work environment. 
LOST: Not seen since >/= 1 month < 3 months. 
DROP: Lost to follow up for > 3 months. 
Transfer out: A patient is referred to another health 
facility for care. 
Functional Status 
• Working: Able to perform usual work in or out 
of the house. 
• Ambulatory: Able to perform activities of 
daily living. 
• Bedridden: Not able to perform activities of 
daily living. 
 
Ethical clearance was obtained from the Joint Committee 
of School of Public Health and Faculty of Informatics, 
Addis Ababa University. Written permissions were 
obtained from SNNPR, Woreda Health Bureau and 
hospital administrations. 
 
SPSS version 15 was used for data analysis. Descriptive 
statistics, repeated measures analysis of variance, 
Kaplan-Meier graphs and Cox regression models were 
performed. Variables with a P-value less than 5% were 
considered as statistically significant. 
 
Results 
Socio-demographic characteristics: 5,664 patient 
records were analyzed in the study of which 56.3% were 
female and 43.7% male (Table 1). The median age was 
30 (range: 14 to 80 years).  4,111 (72.6%) were in age 
group 25 to 40 years. The youngest age group (between 
14 and 24 years) and the older age group (>40 years) 
were 724 (12.8%) and 829 (14.6%) respectively. 
 
Clinical characteristics: From 5,642 known baseline 
WHO stage classifications, 282 (5%) were in WHO stage 
I, 780 (13.8%) in stage II and 4,580 (81.5%) in stage III 
or IV. Of the 5,181 available CD4 cell counts measured 
at and three months before ART initiation, 755 (14.6%) 
had CD4 cell count of less than 50/ml 2,910 (56.2%) had 
between 50 and 200 per  and 1,516 (29.2%) had above 
199 cells per /ml. The median CD4 cell count was 140 
cells per/ml. 
 
The mean (SD) baseline weight for 2,114 male and 3,092 
female participants measured were 54 (8.4) and 47.7 
(8.7), respectively. Functional status at start of ART 
initiation was 562 (10.4%), ambulatory 2,105 (39.0%) 
and working 2,725 (50.5%). 
 
Ethiop. J. Health Dev.    104 
 
Ethiop. J. Health Dev.  2011;25(2) 
Table 1:  Socio-demographic and clinical characteristics of ART patients at start of ART 
initiation in selected hospitals in SNNPR, January 1, 2005 to January 31,2009. 
Characteristics Value 
Sex (n =5,664) n (%) 
   Male 2,477 (43.7%) 
   Female 3.187 (56.3%) 
Age (n=5664, Mean=32.7, SD=8.6, Range= 14 - 80) n (%) 
   14-24 724 (12.8%) 
   25-30 2,128 (37.6%) 
   31-40 1,983 (35.0%) 
   ≥41 829 (14.6%) 
Weight (n=5,505, mean=50.5, SD=9.2 kg)* n (χ ,SD) 
   Male 2,413 (54.1, 8.4) 
   Female 3,092 (47.7, 8.7) 
   <60 kg 4,662 (47.7, 6.7) 
   ≥60 kg 883 (65.1, 5.8) 
CD4 cell count (n=5,181, mean=153.3, median=140, SD=99.2)* n (%) 
   0-49 755 (14.6%) 
   50-199 2,910 (56.2%) 
   >=200 1.516 (29.2%) 
WHO stage at entry (n=5,642)* n (%) 
   Stage I 282 (5.0%) 
   Stage II 780 (13.8%) 
   Stage III 3,571 (63.3%) 
   Stage IV 1,009(17.9%) 
Functional status at entry (n=5,392)* n (%) 
   Bedridden 562 (10.4%) 
   Ambulatory 2,105 (39.0%) 
   Working 2.725 (50.5%) 
Is NVP ARV in baseline regimen (n=5,664) n (%) 
   Yes 3.848 (67.9%) 
   No 1.783 (31.7%) 
   Undetermined 33 (0.6%) 
Baseline ARV regimen type (n=5,664) n (%) 
   Ia(30)-d4t(30)-3TC-NVP 2.866 (50.60%) 
   Ia(40)=d4t(40)-3TC-NVP 276 (4.87%) 
   Ib(30)=d4t(30)-3TC-EFV 1.290 (22.78%) 
   Ib(40)=d4t(40)-3TC-EFV 92 (1.62%) 
   Ic=AZT-3TC-NVP 702 (12.39%) 
   Id=AZT-3TC-EFV 399 (7.04% 
   4a=d4T-3TC-NVP 3 (0.05%) 
   4c=AZT-3TC-NVP 1 (0.02%) 
   4d=AZT-3TC-EFV 2 (0.045%) 
   Other combinations 33 (0.58%) 
*There were missing data 
 
 
Sixty eight percent of the patients 3,848 (68 %) started 
with a Nevirapine combined regimen while 1,783 
(31.7%) initiated with an Efavirenz combined regimen. 
The most common prescribed ARV regimen at baseline 
was a combination of Stavudine + Lamivudine1 + 
Nevirapine (d4t-3TC-NVP) which accounted for 55.5 % 
of the initiation regimens. 
 
Survival and follow up outcome: The end point follow 
up status distribution showed that cumulative proportion, 
of patients alive, dead and dropout were 64.7%, 8.4% and 
13.6% while 10.8% were transferred out to other health 
facilities, LOST and temporary withdrawal of medication 
(STOP) contributes 2.3% and 0.2% respectively by end 
of January 2009.  Overall mean survival time was 43 
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Figure 1: Cumulative survival function of ART patients in selected hospitals of SNNPR, January 1, 2005 to 
January 31, 2009. 
 
Death as an outcome: The cumulative mortality rate was 
74.5 deaths per 1,000 PYO (473 deaths/ 6,352 person-
year observation), in which 70.8% (335/473), 15.2% 
(72/473), 11.0% (52/473) and  2.9%(14/473) deaths 
occurred in the first 6 months, six to one year, one to two 
years, after second year of follow up respectively. 
 
From Cox regression models, a hazard ratio of death in 
patients whose CD4 cell count was less than 50 cells/ml 
and between 50 to 199 cells/ml, relative to ones whose 
CD4 cell count above or equal to 200 cells/ml, were 
found to be 3.176 (CI: 2.304, 4.434) and 1.900 (CI: 
1.405, 2.569) respectively. However, there was no 
significance death rate difference between patients whose 
age group was 25 through 30 and 31 through 40 years. 
 
The survival patterns of ART patients were different at 
the various WHO stage classifications (Figure 2). The 
difference in the risk of death between WHO stage II and 
stage I at any given time is similar (Table 2). However, 
the Hazards Ratio (HR) of WHO stage III and WHO 
stage IV compared to WHO stage I were 4.320 (CI: 
1.375, 13.569) and 5.603(CI: 1.753, 17.905) respectively. 




Figure 2: Survival graph by WHO stage at start of ART initiation in selected hospitals of SNNPR, January 1, 2005 
to January 31, 2009. 
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Figure 3: Survival graph by CD4 cell count at start of ART initiation in selected hospitals of SNNPR, January 1, 2005 to 
January 31, 2009, SNNPR 
 
The hazard ratio of death in patients with Nevirapine 
combined regimen at the beginning of ART was 1.493 
(CI: 1.184, 1.883) times higher than with Non-
Nevirapine regimen at the beginning of ART initiation 
(Table 2). Similarly, a hazard ratio and 95% confidence 
interval for hazard of death in patients with baseline 
functional status ambulatory or bedridden, compared to 
working status were 1.825 (CI: 1.415, 2.347) and 
4.331(CI: 3.156, 5.945) respectively.  
 
From Cox model, gender WHO stage, baseline functional 
status, CD4 cell count, and Nevirapine drug as a 
combined baseline regimen at start of ART initiation had 
significant association in determining the pattern of 
survival and hazard of deaths in ART patients. 
 
Table 2:  Cox regression model:  Factors determining the survival of ART patient in rural public heath hospitals, 
January 1, 2005 to January 31, 2009, SNNPR. 
Covariates             Death as outcome Death or dropout as outcome AHR (95% CI) Sig. AHR (95% CI) Sig. 
Sex     
   Male 1.632 (1.309-2.034) .001 1.362 (1.194-.552) .001 
   Female 1  1  
Age     
   14-24 1  1  
   25-30 0.752 (0.534-1.060) .103 .755 (.625-913) .004 
   31-40 0.763 (5.38-1.083) .130 .717 (.568-.906) .005 
   ≥41 0.976 (662-1.438) .900   
WHO stage     
   WHO Stage I 1  1  
   WHO Stage II 3.018 (.918-9.917) .069 .850 (.581-1.244) .403 
   WHO Stage III 4.320 (1.375-3.569) .012 1.062 (.757-1.489) .727 
   WHO Stage IV 5.603 (1.753-7.905) .004 1.386 (.959-1.975) .083 
Baseline functional status     
   Working 1  1  
   Ambulatory 1.825 (1.417-2.350) .001 1.535 (1.327-.776) .001 
   Bedridden 4.331 (3.156-5.945) .001 2.999 (2.465-.648) .001 
CD4 cell count     
   >=200 1  1  
   50-199 1.900 (1.405-2.569) .001 1.324 (1.129-.553) .001 
   <50 3.176 (2.304-4.434) .001 1.940 (1.604-2.345) .001 
NVP in baseline regimen     
   No 1  1  
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Death or dropout as event of outcome: Permanent 
discontinuation of care can be explained by a rate of 
retention in terms of dead and dropout patients. The 
effect of discontinuation of follow up rate due to death or 
dropout were found to be 75.7% (942/1,245), 13.7% 
(170/1,245), 8.4% (105/1,245) and 2.3%(28/1,245) in the 
first 6 months, six to one year, one to two years, after 
second year of follow up, respectively.  
 
A follow up failure rate ratio of patients with baseline 
functional status, ambulatory and bedridden, compared to 
working were 1.535 (CI: 1.327, 1.776) and 2.999 (CI: 
2.465, 3.648), respectively. In addition, patients with 
CD4 cell count of less than 50 cells/ml and between 50 to 
199 cells/ml, relative to the ones whose CD4 cell count 
was above or equal to 200 cells/ml, were found to be 
1.940 (CI: 1.604, 2.345) and 1.324 (CI: 1.129, 1.553), 
respectively (Table 2).  
 
The hazard of discontinuing follow up rate was higher in 
Nevirapine combined regimen than Efavirenz at baseline 
1.181(CI: 1.031, 1.354).  
Baseline functional status, sex, CD4 cell count, and 
Nevirapine as a combined baseline regimen at start of 
ART initiation were strong predicators of permanent 
discontinuation of ART follow up. 
 
CD4 cell count and body weight: Mean CD4 cell count 
and body weight change patterns differ significantly 
across time. There were significance difference of mean 
CD4 cell count at baseline, month 6, 12 and 24, with an 
increasing pattern. The mean (SD) CD4 cell count result 
for 172 patients were 149.8 (80.8), 278.7 (124.1), 302.2 
(124.6) and 330.5 (137.4) at baseline, month 6, 12 and 24 
respectively (Figure 4). 
 
The estimated marginal mean (SD) of body weight for 
1,221 patients were 50.7(8.7), 55.5(8.7), 56.7(8.8) and 
56.0(8.7) at baseline, month 6, month 12 and month 24 
respectively. There were significant difference of mean 
body weight at baseline, month 6, month 12 and month 
24. However, weight gain decreased at month 24. 
 
 
Figure 4: Profile plot of estimated marginal means of CD4 cell count and body weight change pattern of ART 
patients in SNNPR, January 1, 2005 to January 31, 2009, SNNPR. 
 
Discussion 
In this study the socio-demographic characteristics like 
proportion of females, age distribution and WHO 
classification in ART service delivery program was 
comparable with two Zambia studies (12, 13). A 
community bases South Africa study showed that a 
median age of ART initiation without tuberculoses 
infection was 31 years in the Nevirapine (NVP) group 
and 34 years in the Efavirine (EFV) group with 80% and 
57% of female enrolment, respectively (14). 
 
A significant increase of CD4 cell count was observed 
throughout follow up time. However, the increment is not 
as much as in a similar retrospective cohort study in 
western Kenya which showed a mean CD4 cell count 
increase of 109,160 and 225 at month 0, month 12 and 
month 24 (15).  
 
In this study, males were in a higher risk of death 
compared to females. Similarly, in multi-centric 
observational study in resource-poor settings also 
indicated that being male and CD4 cell count were 
significantly associated with death (16).  
 
Simple laboratory and clinical data independently 
predicted mortality in Durban-South Africa and Northern 
Province of Cameroon studies (17, 18). The present study 
pointed out that CD4 cell count and advanced WHO 
stage were highly associated with mortality. Many 
studies also have indicated similar findings. WHO stage 
II, III and IV patients at start of ART initiation are more 
likely to die earlier than WHO stage I (19, 20). Early 
mortality among adults taking antiretroviral treatment in 
sub-Saharan countries, Meta results from 18 studies, 
concludes that 26% of deaths occur in the first year of 
follow up and early mortality is associated with CD4 cell 
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count and advanced disease stage (21). A two-year 
outcome study in South Africa concluded that ART can 
be provided in resource-limited settings with good patient 
retention and clinical outcome (22). 
 
Higher proportion (68%) of initial regimen prescribed at 
baseline included Nevirapine as a combination. A d4t-
3TC-NVP regimen covered (56%) and d4t-3TC-EFV 
regimen covered 24% of the total prescribed 
antiretroviral regimen. A study in Cote D’Ivoire shows 
that outcome of antiretroviral treatment is not 
significantly associated with initiation of on NVP-based 
regimen, compared to other first line regimens (23). 
However, this study shows that Nevirapine-based 
initiation of regimen has a higher risk of death compared 
to an Efavirenz-based one. 
 
This study indicated that proportions of alive and in care 
at month 6, 12, 24 and 36 were 87.4%, 84.6%, 81.1% and 
77.2%, respectively with cumulative proportion of death 
(8.4%). In Malawi, 74% remained alive and in care, 
while cumulatively 10% were estimated to have died by 
one year. In South Africa and Senegal, cumulative 
mortality estimated at longer durations was 16.9% and 
24.6% by 5 years (24).  
 
The present study showed that patient weight gain at start 
of ART initiation but the increment was not significant at 
month 24.  A Quality care assessment studies conducted 
in the Armed Force General Hospital and Oromiya 
region showed that there were a significant body weight 
gain at month six (25, 26). Another study in two 
developing countries, Cambodia and Kenya, also 
concluded that weight gain at three months is strongly 
associated with survival (27). 
 
This study used routinely collected data and estimation of 
mortality can be under estimated as there are many 
deaths at home. A study in Uganda showed that 29% of 
lost follow up patients were found to be actually deaths. 
The cumulative incidence of death at one, two and three 
years were 1.7%, 2.1% and 2.3%, respectively. However, 
after tracking sampled lost follow up patients, the 
corrected incidence of death at 1, 2, and 3 years were 
7.5%, 10.3% and 12.2% (28). The combined result of 
mortality and discontinuation of follow up rate implies 
that the pattern of death and permanent withdrawal are 
occurring at the same time and pattern. Hence, the reason 
for high rate of withdrawal in the first six months needs 
to be investigated. 
 
This study concluded that gender, WHO stage, CD4 cell 
count, functional status and the existence of NVP-ARV 
drug as a combined regimen at base-line have significant 
effect on determining the mortality and permanent 
discontinuation of treatment in a longer follow up period. 
The authors recommend that priority should be given to 
identify HIV-infected individuals to start ART initiation 
earlier to advanced disease stage, to investigate high 
mortality and permanent discontinuation of follow up 
rate in the first six months, to determine proportion of 
deaths out of the dropouts, and to explore weight loss at 
two years need to be investigated. 
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